Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
AR

AMEX · ARMP

Armata Pharmaceuticals, Inc.

Healthcare · Biotechnology

$3.63

Down-$0.23 (-5.96%)

Updated Oct 10, 2026, 4:49 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
391.74M
P/E ratio
-8.31
Dividend yield
0.00%
52-week range
$3.28 – $14.98
Volume
100.58K
Avg. volume
51.66K

Price performance · ARMP

ARMP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

ARMP closed at $3.63 after 21 trading sessions, down 32.53% for the selected period.

Last close
$3.63
Period change
-32.53%
Period low
$3.31
Period high
$5.55
Daily close
View OHLC price history
ARMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$3.90$3.9525$3.62$3.63100.58K
Oct 8, 2026$3.79$3.91$3.59$3.8670.28K
Oct 7, 2026$3.83$4.07$3.72$3.81103.68K
Oct 6, 2026$3.69$3.93$3.66$3.85114.68K
Oct 5, 2026$3.54$3.68$3.51$3.6656.68K
Oct 2, 2026$3.40$3.55$3.32$3.52124.48K
Oct 1, 2026$3.67$3.78$3.28$3.3176.46K
Sep 30, 2026$3.57$3.74$3.53$3.67127.04K
Sep 29, 2026$3.74$3.74$3.5209$3.5991.79K
Sep 28, 2026$3.66$3.85$3.55$3.7885.79K
Sep 25, 2026$3.60$3.8065$3.5601$3.74100.79K
Sep 24, 2026$3.70$3.8275$3.525$3.62144.44K
Sep 23, 2026$4.20$4.30$3.60$3.64287.06K
Sep 22, 2026$4.27$4.56$4.14$4.20128.36K
Sep 21, 2026$4.24$4.36$4.10$4.2682.9K
Sep 18, 2026$4.07$4.40$4.00$4.18160.61K
Sep 17, 2026$4.32$4.32$4.09$4.10253.54K
Sep 16, 2026$4.40$4.44$3.985$4.07307.47K
Sep 15, 2026$5.24$5.35$4.23$4.40650.23K
Sep 14, 2026$6.17$6.6397$4.73$5.554.74M
Sep 11, 2026$5.30$5.5499$5.26$5.3843.63K

Latest ARMP news

The latest Smart Investors Daily articles mentioning ARMP.

Stock researchCompany · Overview

ARMP research

Overview

Company profile and research snapshot.

Company profile

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ARMP recent ratings
DateFirmRatingTarget
Sep 23, 2026HC Wainwright & Co.Buy—
Feb 23, 2026HC Wainwright & Co.Buy—
Jan 5, 2026Jones TradingBuy—
May 19, 2025HC Wainwright & Co.Buy—
Dec 19, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced issuance of two patents by the United States Patent and Trademark Office ("USPTO") covering its bacteriophage programs, AP-SA02 and AP-PA02. These newly issued U.S. patents

Yahoo · Sep 23, 2026

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $3.7 million in non-dilutive funds from the U.S. Department of War ("DoW") to support activities associated with the Phase 3 development p

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By